Targeting SAMHD1 with hydroxyurea in first‐line cytarabine‐based therapy of newly diagnosed acute myeloid leukaemia: Results from the HEAT‐AML trial

BACKGROUND: Treatment of newly diagnosed acute myeloid leukaemia (AML) is based on combination chemotherapy with cytarabine (ara‐C) and anthracyclines. Five‐year overall survival is below 30%, which has partly been attributed to cytarabine resistance. Preclinical data suggest that the addition of hy...

Descripción completa

Detalles Bibliográficos
Autores principales: Jädersten, Martin, Lilienthal, Ingrid, Tsesmetzis, Nikolaos, Lourda, Magda, Bengtzén, Sofia, Bohlin, Anna, Arnroth, Cornelia, Erkers, Tom, Seashore‐Ludlow, Brinton, Giraud, Géraldine, Barkhordar, Giti S., Tao, Sijia, Fogelstrand, Linda, Saft, Leonie, Östling, Päivi, Schinazi, Raymond F., Kim, Baek, Schaller, Torsten, Juliusson, Gunnar, Deneberg, Stefan, Lehmann, Sören, Rassidakis, Georgios Z., Höglund, Martin, Henter, Jan‐Inge, Herold, Nikolas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9643609/
https://www.ncbi.nlm.nih.gov/pubmed/35934913
http://dx.doi.org/10.1111/joim.13553

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9643609/
https://www.ncbi.nlm.nih.gov/pubmed/35934913
http://dx.doi.org/10.1111/joim.13553

Ejemplares similares